SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2025

SEGMENT INFORMATION

SEGMENT INFORMATION

NOTE 6 – SEGMENT INFORMATION

a. The Company operates in Israel as a single operating segment. The Company’s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.

b. Segment information:

	Three Months Ended March 31,
(U.S. dollars in thousands)	2025		2024
Revenues from customers	$	10,113	$	3,748
Less:
Employee salaries and related expenses		5,205		5,144
Sub-contractors expense		2,689		2,155
Interest expense		6		390
Interest income		(419)		(513)
Depreciation		346		322
Other segment expenses*		6,018		983
Loss before taxes on income		(3,732)		(4,733)
Tax benefit		(113)		(138)
Segment net loss	$	(3,619)	$	(4,595)

* Other expenses included in net income includes raw materials, rent and utilities and others.

c. The following table summarizes the Company’s disaggregation of revenues:

	Three Months Ended March 31,
(U.S. dollars in thousands)	2025		2024
Gaucher disease:
Pfizer (Ireland)	$	6,979	$	1,127
Fiocruz (Brazil)	$	3,016	$	2,550
Fabry disease:
Chiesi (Italy)	$	-	$	-
Total revenues from selling goods	$	9,995	$	3,677
Revenues from license and R&D services	$	118	$	71

d. Long lived assets are located in Israel.